

Editor
World Journal of Clinical Cases
Sylvain G Bourgoïn

September, 22, 2020

Dear Editor:

Can the authors speculate a bit on the mechanism of ROS production by those non-activated segmented cells (i.e., the impact of azacytidine therapy on glycolysis)?

Thank you for your important suggestion.
We added the sentences in discussion section as below.

Li et al reported that shift to a more glycolytic metabolism causes ROS decrease in cancer cells. We speculate that the increase of glycolysis after azacytidine treatment may affect the ROS decrease in MDS cells including neutrophils. Further examination will be required to evaluate this mechanism.

We are looking forward to a rapid and favorable review of our manuscript and its consideration for publication as a report in World Journal of Clinical Cases.

Sincerely yours,

Naomi Shimizu, M.D., Ph.D.
Department of Hematology
Toho University Sakura Medical Center
564-1 Shimoshizu, Sakura-City, Chiba
285-8741, Japan